AbbVie Submits BLA To FDA For Etentamig, Second-Gen BCMA X CD3 Bispecific Antibody T-Cell Engager Administered Intravenously For Treatment Of Adults With Relapsed Or Refractory Multiple Myeloma
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of settings, including in
AbbVie asked the FDA to approve a new cancer medicine called etentamig. This drug fights a tough blood cancer, so watch to see if the FDA says yes.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.